AAAAAA

   
Results: 1-25 | 26-50 | 51-55
Results: 1-25/55
Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
Authors: Jernstrom, H Vesprini, D Bradlow, HL Narod, SA
Citation: H. Jernstrom et al., Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years, J NAT CANC, 93(7), 2001, pp. 554-555
Re: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years
Authors: Narod, SA
Citation: Sa. Narod, Re: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years, J NAT CANC, 93(5), 2001, pp. 396-396
Re: Biologic characteristics of interval and screen-detected breast cancers
Authors: Narod, SA Dube, MP
Citation: Sa. Narod et Mp. Dube, Re: Biologic characteristics of interval and screen-detected breast cancers, J NAT CANC, 93(2), 2001, pp. 151-151
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk
Authors: Jernstrom, H Chu, M Vesprini, D Tao, YZ Majeed, N Deal, C Pollak, M Narod, SA
Citation: H. Jernstrom et al., Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk, MOL GEN MET, 72(2), 2001, pp. 144-154
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women
Authors: Jernstrom, H Deal, C Wilkin, F Chu, W Tao, YZ Majeed, N Hudson, T Narod, SA Pollak, M
Citation: H. Jernstrom et al., Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women, CANC EPID B, 10(4), 2001, pp. 377-384
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
Authors: Runnebaum, IB Wang-Gohrke, S Vesprini, D Kreienberg, R Lynch, H Moslehi, R Ghadirian, P Weber, B Godwin, AK Risch, H Garber, J Lerman, C Olopade, OI Foulkes, WD Karlan, B Warner, E Rosen, B Rebbeck, T Tonin, P Dube, MP Kieback, DG Narod, SA
Citation: Ib. Runnebaum et al., Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives, PHARMACOGEN, 11(7), 2001, pp. 635-638
Intestinal carcinoid tumours in a father and daughter
Authors: Pal, T Liede, A Mitchell, M Calender, A Narod, SA
Citation: T. Pal et al., Intestinal carcinoid tumours in a father and daughter, CAN J GASTR, 15(6), 2001, pp. 405-409
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer
Authors: Warner, E Plewes, DB Shumak, RS Catzavelos, GC Di Prospero, LS Yaffe, MJ Goel, V Ramsay, E Chart, PL Cole, DEC Taylor, GA Cutrara, M Samuels, TH Murphy, JP Murphy, JM Narod, SA
Citation: E. Warner et al., Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer, J CL ONCOL, 19(15), 2001, pp. 3524-3531
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Authors: Narod, SA Sun, P Ghadirian, P Lynch, H Isaacs, C Garber, J Weber, B Karlan, B Fishman, D Rosen, B Tung, N Neuhausen, SL
Citation: Sa. Narod et al., Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study, LANCET, 357(9267), 2001, pp. 1467-1470
Tamoxifen and risk of endometrial cancer
Authors: Narod, SA Pal, Y Graham, T Mitchell, M Fyles, A
Citation: Sa. Narod et al., Tamoxifen and risk of endometrial cancer, LANCET, 357(9249), 2001, pp. 65-66
A genetic epidemiological study of carcinoma of the fallopian tube
Authors: Aziz, S Kuperstein, G Rosen, B Cole, D Nedelcu, R McLaughlin, J Narod, SA
Citation: S. Aziz et al., A genetic epidemiological study of carcinoma of the fallopian tube, GYNECOL ONC, 80(3), 2001, pp. 341-345
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
Authors: Nam, RK Toi, A Vesprini, D Ho, M Chu, W Harvie, S Sweet, J Trachtenberg, J Jewett, MAS Narod, SA
Citation: Rk. Nam et al., V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression, UROLOGY, 57(1), 2001, pp. 199-204
Ovarian cancer, oral contraceptives, and BRCA mutations
Authors: Narod, SA Sun, P Risch, HA
Citation: Sa. Narod et al., Ovarian cancer, oral contraceptives, and BRCA mutations, N ENG J MED, 345(23), 2001, pp. 1706-1707
A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: Confirmation of linkage to TCO1
Authors: Bevan, S Pal, T Greenberg, CR Green, H Wixey, J Bignell, G Narod, SA Foulkes, WD Stratton, MR Houlston, RS
Citation: S. Bevan et al., A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: Confirmation of linkage to TCO1, J CLIN END, 86(8), 2001, pp. 3701-3704
Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: A hospital-based study
Authors: Pal, T Vogl, FD Chappuis, PO Tsang, R Brierley, J Renard, H Sanders, K Kantemiroff, T Bagha, S Goldgar, DE Narod, SA Foulkes, WD
Citation: T. Pal et al., Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: A hospital-based study, J CLIN END, 86(11), 2001, pp. 5307-5312
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history
Authors: Rebbeck, TR Wang, YT Kantoff, PW Krithivas, K Neuhausen, SL Godwin, AK Daly, MB Narod, SA Brunet, JS Vesprini, D Garber, JE Lynch, HT Weber, BL Brown, M
Citation: Tr. Rebbeck et al., Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history, CANCER RES, 61(14), 2001, pp. 5420-5424
HPC2 variants and screen-detected prostate cancer
Authors: Vesprini, D Nam, RK Trachtenberg, J Jewett, MAS Tavtigian, SV Emami, M Ho, M Toi, A Narod, SA
Citation: D. Vesprini et al., HPC2 variants and screen-detected prostate cancer, AM J HU GEN, 68(4), 2001, pp. 912-917
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
Authors: Risch, HA McLaughlin, JR Cole, DEC Rosen, B Bradley, L Kwan, E Jack, E Vesprini, DJ Kuperstein, G Abrahamson, JLA Fan, I Wong, B Narod, SA
Citation: Ha. Risch et al., Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer, AM J HU GEN, 68(3), 2001, pp. 700-710
Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer
Authors: de los Rios, P Jack, E Kuperstein, G Lynch, H Lubinski, J Narod, SA
Citation: P. De Los Rios et al., Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer, AM J HU GEN, 68(2), 2001, pp. 546-546
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadianand Yemenite Jewish hereditary breast cancer families
Authors: Manning, AP Abelovich, D Ghadirian, P Lambert, JA Frappier, D Provencher, D Robidoux, A Peretz, T Narod, SA Mes-Masson, AM Foulkes, WD Wang, TL Morgan, K Fujiwara, TM Tonin, PN
Citation: Ap. Manning et al., Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadianand Yemenite Jewish hereditary breast cancer families, HUMAN HERED, 52(2), 2001, pp. 116-120
Clinical characteristics of genetically determined breast cancer
Authors: Narod, SA
Citation: Sa. Narod, Clinical characteristics of genetically determined breast cancer, MANAGEMENT OF PATIENTS AT HIGH RISK FOR BREAST CANCER, 2001, pp. 56-62
High risk genes predisposing to prostate cancer development - do they exist?
Authors: Singh, R Eeles, RA Durocher, F Simard, J Edwards, S Badzioch, M Kote-Jarai, Z Teare, D Ford, D Dearnaley, D Ardern-Jones, A Murkin, A Dowe, A Shearer, R Kelly, J Labrie, F Easton, D Narod, SA Tonin, PN Foulkes, WD
Citation: R. Singh et al., High risk genes predisposing to prostate cancer development - do they exist?, PROSTATE C, 3(4), 2000, pp. 241-247
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Authors: Foulkes, WD Chappuis, PO Wong, N Brunet, JS Vesprini, D Rozen, F Yuan, ZQ Pollak, MN Kuperstein, G Narod, SA Begin, LR
Citation: Wd. Foulkes et al., Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome, ANN ONCOL, 11(3), 2000, pp. 307-313
Serum human glandular kallikrein-2 protease levels predict the presence ofprostate cancer among men with elevated prostate-specific antigen
Authors: Nam, RK Diamandis, EP Toi, A Trachtenberg, J Magklara, A Scorilas, A Papnastasiou, PA Jewett, MAS Narod, SA
Citation: Rk. Nam et al., Serum human glandular kallikrein-2 protease levels predict the presence ofprostate cancer among men with elevated prostate-specific antigen, J CL ONCOL, 18(5), 2000, pp. 1036-1042
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer
Authors: Chappuis, PO Kapusta, L Begin, LR Wong, N Brunet, JS Narod, SA Slingerland, J Foulkes, WD
Citation: Po. Chappuis et al., Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer, J CL ONCOL, 18(24), 2000, pp. 4045-4052
Risultati: 1-25 | 26-50 | 51-55